Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SINOVAC BIOTECH LTD.

(SVA)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sinovac Biotech Ltd. Announces New Preliminary Data on its Inactivated COVID-19 Vaccine CoronaVac

11/09/2021 | 07:00am EST

SINOVAC Biotech Ltd. announced new preliminary data on its inactivated COVID-19 vaccine CoronaVac?. The results from statistics analysis under blind status indicated that CoronaVac? is safe for healthy people of different races in the pediatric and adolescent population ranging from 3 to 17 years of age. The multi-center, case-driven, randomized, double-blind, and placebo-controlled phase III study is currently being conducted in South Africa, Chile, Malaysia, and the Philippines. As of October 2021, a total of 2,140 participants ranging from 6 months to 17 years of age have been enrolled in the study, including 684 participants in the safety subgroup. The blind safety data analysis for this subgroup shows a good safety profile among healthy participants aged from 3 to 17 years. The research will continue to be carried out in 6 months infants and young children. The research results will provide a stronger scientific basis for countries to safely carry out the new crown vaccination work for minors over 6 months of age. Results from the safety data for the 684 participants in the safety subgroup found that the incidence of adverse effects after the second dose of vaccination was much lower than that of the first dose. Local and systemic adverse effects were mainly pain at the injection site and headache and fever, respectively. Severity was milder at grades 1 and 2, and no suspicious and unexpected serious adverse effects occurred. The preliminary results of this international multi-center phase III clinical study have shown that the overall incidence of adverse effects among subjects is similar to that among domestic adolescents and children phase I/II clinical trials. The findings suggest that CoronaVac? has a good safety profile among the healthy pediatric and adolescent population ranging from 3 to 17 years old. Further research results are expected to provide a scientific basis for safe vaccination with CoronaVac? for infants as young as 6 months of age. Since September of this year, several countries, including Chile, Ecuador, El Salvador, Colombia, Cambodia, and Indonesia, have approved the use of CoronaVac? for healthy people in the 3-17 age range. In China, as of the end of October, more than 110 million doses of CoronaVac? have been administered to groups of minors under 18 years of age.


ę S&P Capital IQ 2021
All news about SINOVAC BIOTECH LTD.
01/05Zhejiang Jinyi Shengshi Bioengineering Co., Ltd. announced that it has received $31.4 m..
CI
01/04WHO sees more evidence that Omicron causes milder symptoms
RE
2021Sinovac COVID-19 shot with Pfizer booster less effective against Omicron - study
RE
2021Sinovac Biotech Swings to H1 Profit Amid Sales Boost
MT
2021SINOVAC BIOTECH : Reports Unaudited First Half of 2021 Financial Results - Form 6-K
PU
2021SINOVAC Reports Unaudited First Half of 2021 Financial Results
BU
2021Sinovac Biotech Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
2021Refugees lack COVID shots because drugmakers fear lawsuits - documents
RE
2021SINOVAC BIOTECH : Antigua Court of Appeal Rules in Favor of SINOVAC, Upholds 2018 Judgment..
PU
2021Antigua Court of Appeal Rules in Favor of SINOVAC, Upholds 2018 Judgment
BU
More news
Financials (USD)
Sales 2020 511 M - -
Net income 2020 110 M - -
Net cash 2020 1 040 M - -
P/E ratio 2020 6,66x
Yield 2020 -
Capitalization 642 M 642 M -
EV / Sales 2019 1,86x
EV / Sales 2020 -0,78x
Nbr of Employees 1 959
Free-Float 24,1%
Chart SINOVAC BIOTECH LTD.
Duration : Period :
Sinovac Biotech Ltd. Technical Analysis Chart | SVA | AGP8696W1045 | MarketScreener
Income Statement Evolution
Managers and Directors
Wei Dong Yin Chairman, President, CEO, Secretary & MD
Nan Wang CFO & Vice President-Business Development
Qiang Gao Chief Operating Officer & Vice President
Yuk Lam Lo Independent Director
Jian Li Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SINOVAC BIOTECH LTD.0.00%642
CSL LIMITED-11.13%88 334
WUXI BIOLOGICS (CAYMAN) INC.-13.88%46 306
SAMSUNG BIOLOGICS CO.,LTD.-16.17%43 094
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-8.47%32 656